Bevacizumab (AVASTIN®, BVZ) is a recombinant humanized monoclonal immunoglobulin antibody, with antihuman vascular endothelial growth factor (VEGF) activity, approved as an antitumoral agent in the treatment of several tumors such as colorectal and lung cancer, and renal cell carcinoma [1]. This evidence concerns the gene VEGFA and hereditary clear cell renal cell carcinoma.